Elizabeth Blake Schwert - Profile and Investment Details

Investor Profile

Elizabeth Blake Schwert is a Venture Capital based in Boston, United States with a diverse investment portfolio that includes companies such as Enara Bio, Direct Flow Medical, Kesios Therapeutics, Pulmocide, myOrthos, CSA Medical, Avitide, Sutro Biopharma, CardioFocus, TopiVert, Aligned TeleHealth, LOQUS23 THERAPEUTICS, CytoMed Therapeutics, Bicycle Therapeutics, Jet Health, Centauri Health Solutions, PanOptica, Halscion, Inc., Urgent Team Holdings, Inc., Arsanis, Atopix Therapeutics, Bardy Diagnostics, EBT Medical, Cibiem, Inc., CardioKinetix, Amwell, Avrobio, NKT Therapeutics, Pionyr Immunotherapeutics, Healthify, Zarodex Therapeutics, Misonix, Sitryx Therapeutics, KalVista Pharmaceuticals, Good Start Genetics, Aerocare Holdings, Cerevance, Karus Therapeutics, Ribometrix, Transposon Therapeutics, Spinal Kinetics, Catamaran Bio, Thesan Pharmaceuticals, Autifony Therapeutics, ReShape Lifesciences, Leiter's, Artios Pharma, Endotronix, Maestro Health, EBR Systems, ValenTx, AllianceCare, Xilio Therapeutics, Evidation Health, SUN Behavioral Health, Caraway Therapeutics, Soffio Medical, Zerigo Health, VHSquared, AqueSys, Doctors of Physical Therapy, AcuFocus, Cellinta, Schweiger Dermatology, Deciphera Pharmaceuticals, Delenex Therapeutics. Over time, Elizabeth Blake Schwert has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Elizabeth Blake Schwert is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Genetics, Women Founded, Medical Testing, Women Led, Life Science, Information Services, Biotech, Analytics, Medical Device, Data Centers, Healthcare, Biotechnology, Genomics, Clinical Trials, Health Diagnostics, Medical, Big Data, Therapeutics, Pharmaceuticals, Biopharma may find it worthwhile to explore potential connections with Elizabeth Blake Schwert, as their portfolio suggests a familiarity and interest in this area.

Understanding Elizabeth Blake Schwert’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.